Search Clinical Trials
583,298 trials
ID
Status
Phase
Title
Sponsor
NCT07569588
Improving Patient Assessment After Acute Kidney Injury (AKI)University Hospitals of Derby and Burton NHS Foundation TrustRecruiting
NCT07569588Recruiting
—
Improving Patient Assessment After Acute Kidney Injury (AKI)University Hospitals of D...
NCT07569315
Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger Ovulation in Hyper-respondersBedaya HospitalNot Yet RecruitingPhase 2
NCT07569315Not Yet Recruiting
Phase 2
Successive Doses of GnRH Agonist Versus Single Dose of GnRH Agonist to Trigger O...Bedaya Hospital
NCT07569770
Comparing High-Protein and Low-Protein Multi-Ingredient Supplements for Body Composition and Performance in Elite Rugby PlayersUniversity of TaipeiCompletedNot Applicable
NCT07569770Completed
Not Applicable
Comparing High-Protein and Low-Protein Multi-Ingredient Supplements for Body Com...University of Taipei
NCT07571291
DEVELOPMENT OF INNOVATIVE TARGETED LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF INFLAMMATORY DRIVEN PULMONARY FIBROSISFondazione IRCCS Policlinico San Matteo di PaviaActive Not Recruiting
NCT07571291Active Not Recruiting
—
DEVELOPMENT OF INNOVATIVE TARGETED LIPOSOMAL FORMULATIONS FOR THE TREATMENT OF I...Fondazione IRCCS Policlin...
NCT07569926
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical RecurrenceBlue Earth DiagnosticsNot Yet RecruitingPhase 4
NCT07569926Not Yet Recruiting
Phase 4
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Managemen...Blue Earth Diagnostics
NCT07569328
Low-dose Colchicine for CABG Graft Failure PreventionBeijing Anzhen HospitalNot Yet RecruitingNot Applicable
NCT07569328Not Yet Recruiting
Not Applicable
Low-dose Colchicine for CABG Graft Failure PreventionBeijing Anzhen Hospital
NCT07569029
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan AntibodiesDepartment of Health and Human Services (HHS)Not Yet RecruitingPhase 1
NCT07569029Not Yet Recruiting
Phase 1
A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA...Department of Health and...
NCT07570797
Mentor-Supported Digital Literacy TrainingErzincan Binali Yildirim UniversitesiNot Yet RecruitingNot Applicable
NCT07570797Not Yet Recruiting
Not Applicable
Mentor-Supported Digital Literacy TrainingErzincan Binali Yildirim...
NCT07571122
Cognitive Training for Pain , Balance and Foot Function in Plantar FasciitisBeni-Suef UniversityRecruitingNot Applicable
NCT07571122Recruiting
Not Applicable
Cognitive Training for Pain , Balance and Foot Function in Plantar FasciitisBeni-Suef University
NCT07568782
Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.Lille UniversityNot Yet Recruiting
NCT07568782Not Yet Recruiting
—
Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Im...Lille University
NCT07569458
Online Personalized Psychological Intervention for Patients With Heart Disease and Depression or Anxiety (MY-CHOICE)Aalborg University HospitalRecruitingNot Applicable
NCT07569458Recruiting
Not Applicable
Online Personalized Psychological Intervention for Patients With Heart Disease a...Aalborg University Hospit...
NCT07570147
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult ParticipantsAbbVieNot Yet RecruitingPhase 1
NCT07570147Not Yet Recruiting
Phase 1
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Asc...AbbVie
NCT07570849
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic CholangiocarcinomaShanghai Zhongshan HospitalRecruitingPhase 2
NCT07570849Recruiting
Phase 2
Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment f...Shanghai Zhongshan Hospit...
NCT07568808
Core Stabilization and Kinesthetic Training in Diplegic CPUniversity of LahoreCompletedNot Applicable
NCT07568808Completed
Not Applicable
Core Stabilization and Kinesthetic Training in Diplegic CPUniversity of Lahore
NCT07568600
Development and Clinical Study of Burn Wound Nursing Dressing Based on Sodium Hyaluronate Carbomer Composite HydrogelThe First Affiliated Hospital of Xinxiang Medical CollegeNot Yet RecruitingNot Applicable
NCT07568600Not Yet Recruiting
Not Applicable
Development and Clinical Study of Burn Wound Nursing Dressing Based on Sodium Hy...The First Affiliated Hosp...
NCT07570186
Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male ParticipantsOnconic Therapeutics Inc.Not Yet RecruitingPhase 1
NCT07570186Not Yet Recruiting
Phase 1
Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy...Onconic Therapeutics Inc.
NCT07571057
Effects of an 8-week Jump Squat 15-m Swimming Start SwimmersFederal University of VicosaActive Not RecruitingNot Applicable
NCT07571057Active Not Recruiting
Not Applicable
Effects of an 8-week Jump Squat 15-m Swimming Start SwimmersFederal University of Vic...
NCT07568704
Image Evaluation of Intalight Dream OCTA Scans With Optos FA & ICGA ImagesIntalight, IncRecruiting
NCT07568704Recruiting
—
Image Evaluation of Intalight Dream OCTA Scans With Optos FA & ICGA ImagesIntalight, Inc
NCT07570303
Promoting Walking Among Older Adults Through Nostalgia-Based Messages and Step-MonitoringCatholic University, ItalyNot Yet RecruitingNot Applicable
NCT07570303Not Yet Recruiting
Not Applicable
Promoting Walking Among Older Adults Through Nostalgia-Based Messages and Step-M...Catholic University, Ital...
Result Breakdown
Not yet recruiting10 (50%)
Recruiting5 (25%)
Completed3 (15%)
Active, not recruiting2 (10%)
not_applicable10 (50%)
Not Specified4 (20%)
Phase 13 (15%)
Phase 22 (10%)
Phase 41 (5%)